STOCK TITAN
  1. Home
  2. Sec-filings
  3. RPRX
  4. [Form 4] Royalty Pharma plc Insider Trading Activity

Royalty Pharma (RPRX) EVP-linked LLC sells 20,000 Class A shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Royalty Pharma EVP Marshall Urist, through Sandy Lamm LLC, sold 20,000 Class A Ordinary Shares of Royalty Pharma plc on January 16, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025. The shares were sold at a weighted average price of $39.5173 in multiple trades between $39.37 and $39.76 per share. Following the sale, Sandy Lamm LLC held 40,000 shares, an IRA associated with the reporting person held 19,020 shares, and 7,398 shares were held directly. In addition, the reporting person and family vehicles hold limited partnership and holding company interests exchangeable into 2,474,120 and 1,356,528 Class A Ordinary Shares, with certain Class E shares subject to vesting conditions.

Positive

  • None.

Negative

  • None.
Insider Urist Marshall
Role EVP, Research & Investments
Sold 20,000 shs ($790K)
Type Security Shares Price Value
Sale Class A Ordinary Shares 20,000 $39.5173 $790K
holding Class A Ordinary Shares -- -- --
holding Class A Ordinary Shares -- -- --
Holdings After Transaction: Class A Ordinary Shares — 40,000 shares (Indirect, By Sandy Lamm LLC); Class A Ordinary Shares — 7,398 shares (Direct)
Footnotes (1)
  1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.37 to $39.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Urist Marshall
(Last) (First) (Middle)
C/O ROYALTY PHARMA PLC
110 EAST 59TH STREET
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Research & Investments
3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Ordinary Shares 01/16/2026 S(1) 20,000 D $39.5173(2) 40,000 I By Sandy Lamm LLC
Class A Ordinary Shares 19,020 I By IRA
Class A Ordinary Shares 7,398 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.37 to $39.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.
/s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist 01/20/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Royalty Pharma (RPRX) report for Marshall Urist?

The filing shows that Marshall Urist, EVP, Research & Investments of Royalty Pharma plc, had an entity associated with him, Sandy Lamm LLC, sell 20,000 Class A Ordinary Shares of Royalty Pharma on January 16, 2026.

At what price were the 20,000 Royalty Pharma (RPRX) shares sold?

The 20,000 Class A Ordinary Shares were sold at a weighted average price of $39.5173 per share, with individual trade prices ranging from $39.37 to $39.76 per share.

Was the Royalty Pharma (RPRX) insider sale made under a 10b5-1 trading plan?

Yes. The filing states that all reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2025.

How many Royalty Pharma (RPRX) shares does Sandy Lamm LLC hold after the sale?

After the reported sale, Sandy Lamm LLC held 40,000 Class A Ordinary Shares of Royalty Pharma plc.

What are Marshall Urist’s other reported Royalty Pharma (RPRX) share holdings?

Besides the Sandy Lamm LLC position, the filing reports 19,020 Class A Ordinary Shares held indirectly via an IRA and 7,398 Class A Ordinary Shares held directly by the reporting person.